Access

Article

Nature 436, 356-362 (21 July 2005) | doi:10.1038/nature03711; Received 29 March 2005; Accepted 3 May 2005

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

Qin Yang1,4, Timothy E. Graham1,4, Nimesh Mody1, Frederic Preitner1, Odile D. Peroni1, Janice M. Zabolotny1, Ko Kotani1, Loredana Quadro2,3 & Barbara B. Kahn1

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
  2. Institute of Cancer Research, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
  3. †Present address: Department of Food Science, Rutgers–The State University of New Jersey, New Brunswick, New Jersey 08901, USA
  4. *These authors contributed equally to this work

Correspondence to: Barbara B. Kahn1 Correspondence and requests for materials should be addressed to B.B.K. (Email: bkahn@bidmc.harvard.edu).

Top

In obesity and type 2 diabetes, expression of the GLUT4 glucose transporter is decreased selectively in adipocytes. Adipose-specific Glut4 (also known as Slc2a4) knockout (adipose-Glut4-/-) mice show insulin resistance secondarily in muscle and liver. Here we show, using DNA arrays, that expression of retinol binding protein-4 (RBP4) is elevated in adipose tissue of adipose-Glut4-/- mice. We show that serum RBP4 levels are elevated in insulin-resistant mice and humans with obesity and type 2 diabetes. RBP4 levels are normalized by rosiglitazone, an insulin-sensitizing drug. Transgenic overexpression of human RBP4 or injection of recombinant RBP4 in normal mice causes insulin resistance. Conversely, genetic deletion of Rbp4 enhances insulin sensitivity. Fenretinide, a synthetic retinoid that increases urinary excretion of RBP4, normalizes serum RBP4 levels and improves insulin resistance and glucose intolerance in mice with obesity induced by a high-fat diet. Increasing serum RBP4 induces hepatic expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK) and impairs insulin signalling in muscle. Thus, RBP4 is an adipocyte-derived 'signal' that may contribute to the pathogenesis of type 2 diabetes. Lowering RBP4 could be a new strategy for treating type 2 diabetes.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Metabolism A is for adipokine

Nature News and Views (21 Jul 2005)

You are what you secrete

Nature Medicine News and Views (01 Aug 2001)

See all 5 matches for News And Views